Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO FDA approval to deliver the simplest and fastest ...
Lower kidney function is associated with elevated Alzheimer’s blood biomarkers, raising implications for dementia diagnosis ...
The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT ...
This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...
People with reduced kidney function may have higher levels of several blood markers commonly used in Alzheimer’s disease research, according to a large new review published in the Journal of the ...
Background Secondary prevention is critical for patients with established atherosclerotic cardiovascular diseases (ASCVD).
Once again, your party is left with backs to the wall. Defending Nils is a challenge, but along the way you'll pick up three new party members. Be sure to recruit Lyn for the battle, and either bring ...
The Alzheimer’s ‘clock’ could make it easier to treat the disease early, before memory problems appear. A simple blood test ...
A protein lurking around in the blood can help with the accurate diagnosis of Alzheimer's disease. In a recent study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results